CapsoVision Inc (CV)

Currency in USD
6.110
-0.200(-3.17%)
Closed·
6.1100.000(0.00%)
·
CV is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
6.0106.370
52 wk Range
4.50015.370
Key Statistics
Prev. Close
6.31
Open
6.26
Day's Range
6.01-6.37
52 wk Range
4.5-15.37
Volume
178.66K
Average Volume (3m)
171.96K
1-Year Change
16.826%
Book Value / Share
0,53
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CV Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
9.500
Upside
+55.48%
Members' Sentiments
Bearish
Bullish
ProTips
Operates with a moderate level of debt

CapsoVision Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 9.500
(+55.48% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
StoneX
Buy10.00+63.67%-MaintainNov 13, 2026
Roth/MKM
Buy9.00+47.30%-New CoverageAug 28, 2026
Titan Partners
Buy10.00+63.67%-New CoverageAug 26, 2026
Benchmark
Buy10.00+63.67%-MaintainAug 14, 2026
Benchmark
Buy10.00+63.67%-MaintainMay 15, 2026

CapsoVision Inc Earnings Call Summary for Q3/2026

  • Q3 revenue rose 1% to $3.6M; net loss narrowed to $7.3M ($0.15/share) from $7.9M ($0.17/share) year-over-year as operating expenses fell 8.1%.
  • FDA-cleared AI Highlights tool launched Nov. 2 for CapsoCam Plus; management expects full commercial impact to materialize in 2027, not current quarter.
  • Gross margin compressed to 49% from 54% due to higher material costs, inventory obsolescence, and stock-based compensation expenses.
  • Company raised $19.5M in capital, ending quarter with $21.8M cash; plans FDA submission for CapsoCam Colon by year-end 2026 after study completion.
  • Analysts set price targets of $9-$10 (50% upside); management forecasts stronger H2 2026 as large customers awaited FDA clearance before purchasing.
Last Updated: 2026/11/13, 00:14
Read Full Transcript

Earnings

Latest Release
Nov 12, 2026
EPS / Forecast
-0,15 / -0,11
Revenue / Forecast
3,57M / --
EPS Revisions
Last 90 days

CV Income Statement

Compare CV to Peers and Sector

Metrics to compare
CV
Peers
Sector
Relationship
P/E Ratio
−11.2x2.8x−0.2x
PEG Ratio
−0.17−0.150.00
Price/Book
12.4x2.5x2.6x
Price / LTM Sales
23.5x2.4x2.6x
Upside (Analyst Target)
55.5%98.5%76.9%
Fair Value Upside
Unlock21.1%14.9%Unlock

CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). It also provides CapsoCloud cloud-based software-as-a-service ecosystem as an off-premises video access and download solution; CapsoView, a data access reading device for viewing capsule videos; CapsoAccess, a Capsule data access system; and CapsoRetrieve, a retrieval kit to recover the capsule using a magnetic wand, as well as capsule video reading services. The company serves gastrointestinal medical practices, clinics, and hospitals. It sells its products to distributor customers who resell products. The company was formerly known as Capso Vision Inc. and changed its name to CapsoVision, Inc. in May 2016. CapsoVision, Inc. was incorporated in 2005 and is headquartered in Saratoga, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
4,10M8,20%27,98M
Other Institutional Investors
4,96M9,91%33,83M
Public Companies & Retail Investors
40,98M81,89%279,50M
Total
50,05M100,00%341,32M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Kioxia Holdings Corporation6,89%3 446 92523 508
BlackRock, Inc.3,79%1 896 08812 931

FAQ

What Is the CapsoVision (CV) Stock Price Today?

The CapsoVision stock price today is 6,110 USD.

What Stock Exchange Does CapsoVision Trade On?

CapsoVision is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for CapsoVision?

The stock symbol for CapsoVision is "CV."

What Is the CapsoVision Market Cap?

As of today, CapsoVision market cap is 338,280M USD.

What Is CapsoVision's Earnings Per Share (TTM)?

The CapsoVision EPS (TTM) is -0,60.

From a Technical Analysis Perspective, Is CV a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has CapsoVision Stock Split?

CapsoVision has split 0 times.

How Many Employees Does CapsoVision Have?

CapsoVision has 99 employees.

What is the current trading status of CapsoVision (CV)?

As of Nov 21, 2026, CapsoVision (CV) is trading at a price of 6,110 USD, with a previous close of 6,310 USD. The stock has fluctuated within a day range of 6,010 USD to 6,370 USD, while its 52-week range spans from 4,500 USD to 15,370 USD.

What Is CapsoVision (CV) Price Target According to Analysts?

The average 12-month price target for CapsoVision is 9,500 USD, with a high estimate of 10 USD and a low estimate of 9 USD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +55,48% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.